Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
san francisco blog main
4
×
national top stories
new york blog main
san diego blog main
san francisco top stories
boston blog main
boston top stories
bristol-myers squibb
clinical data
drugs
gene therapy
new york top stories
san diego top stories
acadia pharmaceuticals
adverum biotechnologies
aimmune
alk
allergan
amgen
astellas pharma
atlas venture
audentes therapeutics
avalon ventures
aveo oncology
avidity biosciences
biogen
biotech
bluebird bio
boston
cannabidiol
cerevel therapeutics
dravet syndrome
drug pricing
duchenne muscular dystrophy
dyne therapeutics
egfr
epidiolex
What
data
4
×
drug
4
×
ago
approved
medicine
rare
advanced
arrival
award
battle
bio
biotechs
cancer
cannabis
considering
death
decades
dems
derivative
disease
diseases
dyne
early
epilepsy
expected
experimental
eyes
fatty
fda
form
genetic
given
gw
gw’s
having
horizon
humans
immunotherapy
intercept
ipo
Language
unset
Current search:
drug
×
" san francisco blog main "
×
data
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug